| Project/Area Number |
18590727
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Gastroenterology
|
|---|
| Research Institution | Mie University |
|---|
Principal Investigator |
SHIRAKI Katsuya Mie University, Hospital, Lecturer (90263003)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
SUGIMOTO Kazushi Mie University, Hospital, Medical doctor (60378370)
UCHIDA Kazuhiko Tsukuba University, 人間総合科学研究科, 准教授 (90211078)
村田 一素 三重大学, 医学部附属病院, 助手 (40345971)
|
|---|
| Project Period (FY) |
2006 – 2007
|
| Project Status |
Completed (Fiscal Year 2007)
|
| Budget Amount *help |
¥3,800,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥300,000)
Fiscal Year 2007: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2006: ¥2,500,000 (Direct Cost: ¥2,500,000)
|
|---|
| Keywords | Proteomics / Hepatitis / Hepatocellular carcinoma / アポトーシス / stat |
|---|
| Research Abstract |
The major plasma proteins mask the presence of circulating low abundant peptides that may be potential biomarkers of a particular disease state1. Although serum peptides may function as surrogate markers for the detection of cancer, there is no convincing data that have identified valuable low abundance peptides of cellular origin. Here we have established a differential and quantitative peptidomic methodology using mass spectrometry(MS) to screenfor such masked peptide biomarkers. Comprehensive analysis of 184 serum samples has identified peptides that demonstrate remarkable diagnostic potential in the differential diagnosis of chronic liver disease ; chronic hepatitis(CH), liver cirrhosis(LC) and hepatocellular carcinoma(HCC) . Moreover, we have identified twelve cell-derived peptides that are associated with cancer and also a glycosylated peptide, which showed the diagnostic accuracy in patients with HCC. Further evaluation using an immunoMS(IMS) assay confirmed the diagnostic value of this latter molecule. Our findings thus indicate that circulating peptides in the blood, particularly those of a cellular origin, are potential biomarkers, and could have an impact on molecular diagnostics and therapeutic intervention in cases of chronic liver disease.
|
